The particulars: liraglutide · ten weeks · 30 °C.
I would like to define my thresholds before I have a result, for obvious reasons.
I want a plan with explicit stopping rules, not just steps.
What does a sensible plan look like, and what are the decision points?
ten weeks is 70 days, and at 30 °C the ten-degree rule of thumb makes that roughly 396 refrigerated days of equivalent exposure. 30 °C is 25 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 5.7 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. Compare that against what the certificate covers, which is the material as it left the laboratory on the date of analysis and nothing after it. 396 equivalent days is past the point where the original figure is evidence about the current vial, so the honest answer is that you no longer have a certificate for what you are holding. If you do re-test, send it for content as well as purity; the 70 days will have moved one of them further than the other.
The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.
Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
Assume segregation is possible, and design your sampling to catch it if it exists.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsIf a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
Put another way, if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
If testing multiple vials, state how many you tested and why you chose those vials.
edited 4 Jun 2025 by kwn_analytical — added the placebo-arm figures
Batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.